CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Dr. Jacobson on the Significance of CD19-Targeted CAR T-Cell Therapy in B-Cell Malignancies

October 27th 2020

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Cellular and Targeted Therapies Push the Envelope in Hematologic Malignancies

October 27th 2020

Jeffrey Zonder, MD, discusses the explosion of targeted therapies, along with the rise of cellular therapy, in hematologic malignancies.

Off-the-Shelf CAR T-Cell Product CTX110 Shows Early Activity in Relapsed/Refractory CD19+ B-Cell Malignancies

October 23rd 2020

The investigational wholly-owned allogeneic CAR T-cell therapy CTX110 demonstrated dose-dependent efficacy and responses in patients with relapsed/refractory CD19-positive B-cell malignancies.

Dr. Hill on the FDA Approval of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

October 20th 2020

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.

CAR T-Cell Therapy Enters a New Era in Lymphomas, But More Lessons to Learn

October 20th 2020

Brian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.

How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

October 16th 2020

Dr. Hill on Future Research With CAR T-Cell Therapy in B-Cell Lymphomas

October 12th 2020

Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.

Dr. Vesole on Developing Off-the-Shelf CAR T-Cell Therapy in Multiple Myeloma

October 9th 2020

David H. Vesole, MD, PhD, discusses the importance of developing off-the-shelf CAR T-cell therapy ​products in multiple myeloma.

Dr. Hill on Managing CRS in Patients Treated With CAR T-Cell Therapy

October 9th 2020

Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.

Dr. Deol on the Curative Potential of CAR T-Cell Therapy in ALL

October 8th 2020

Abhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.

Dr. Deol on the Utility of Tisagenlecleucel in ALL

October 7th 2020

Abhinav Deol, MD, discusses the approval of the CAR T-cell therapy tisagenlecleucel for pediatric patients with acute lymphoblastic leukemia.

Dr. Gajra on Adverse Effects Associated With CAR T-Cell Therapy in Hematologic Malignancies

October 6th 2020

Ajeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.

Dr. Vesole on the Advantages of CAR T-Cell Therapy in Multiple Myeloma

October 5th 2020

David H. Vesole, MD, PhD, discusses the advantages of CAR T-cell therapy in multiple myeloma.

Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL

September 30th 2020

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL

September 28th 2020

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

AUTO3 CAR T-Cell Product Plus Pembrolizumab Shows Clinical Activity, Tolerability in Relapsed/Refractory DLBCL

September 23rd 2020

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Zonder on the ZUMA-2 and ZUMA-5 Trials in MCL and iNHL

September 22nd 2020

Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.

Dr. Deol on the Nuances of Utilizing CAR T-Cell Therapy in Lymphoma and Leukemia

September 22nd 2020

Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.

FDA Grants Priority Review to Idecabtagene Vicleucel for Multiple Myeloma

September 22nd 2020

The FDA has granted a priority review designation to a biologics license application for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma who have received at least 3 previous therapies.

Dr. Costa on the Promising Role of CAR T-Cell Therapy in Multiple Myeloma

September 14th 2020

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.